India approves selumetinib for neurofibro matosis type 1 children

D

rugs Controller General of India (DCGI) has cleared Selumetinib 10 mg and 25mg capsules for the treatment of Pediatric patients above 3 years of age and older with neurofibromatosis type 1 (NF1) and who have symptomatic, inoperable plexiform neurofibromas (PN). With this approval, the India unit of UK drugmaker  AstraZeneca has already started importing and marketing the drug in the domestic market.